The present invention relates to compounds of general formula (1) that are inhibitors of Janus Kinase (JAK) a family of tyrosine kinases that are involved in inflammatory conditions autoimmune diseases proliferative diseases allergy transplant rejection diseases involving impairment of cartilage turnover congenital cartilage malformations and/or diseases associated with hypersecretion of IL6 or interferons. In particular the compound of the invention inhibits JAK1 and/or JAK2 and/or JAK3 sub families. The present invention also provides methods for the production of the compounds of the invention pharmaceutical compositions comprising the compounds of the invention their tautomeric forms and their pharmaceutically acceptable salts.
